Skip to main content

Editorial label review

Alloy side effects: weight gain

Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms

Quick answer

Weight gain shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.

What Alloy prescribes and why it matters for weight gain

Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. Weight-change entries appear in every oral and transdermal estradiol PIL used by these telehealth programmes.

Common label-level side effects

Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.

  • Fluid retention causing 1–2 lb of early weight change, listed in the estradiol PIL Section 6 adverse-reaction table at 1–10% frequency
  • Bloating and increased appetite, both documented in the Prometrium (micronized progesterone) PIL Section 6.1
  • Weight changes that stabilise once dosing settles — clinical trials did not show sustained fat gain versus placebo

Serious label-level warnings

Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.

  • Sudden weight gain paired with leg swelling, shortness of breath, or chest pain — potential venous thromboembolism per estradiol PIL boxed warning
  • Rapid abdominal swelling with pain — flagged as a Section-5 warning for hepatic events on the estradiol label

When to contact your clinician

Call your clinician if you gain more than 5 lb in a week, notice one-sided leg swelling, or develop shortness of breath — the estradiol PIL requires prompt evaluation for possible thromboembolism.

Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.

What to ask your provider

  • “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for weight gain?”
  • “Is my weight gainlikely a labelled adverse reaction, or something separate that needs its own workup?”
  • “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
  • “What is the plan if weight gaindoes not settle within 2–3 cycles?”

Frequently asked questions

How often does weight gain happen on Alloy?
Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for weight gain described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
When should I stop Alloy because of weight gain?
Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
Is weight gain on the FDA label for Alloy's medications?
Weight-change entries appear in every oral and transdermal estradiol PIL used by these telehealth programmes.
Is weight gain caused by menopause itself?
Weight gain can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/weight-gain explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.

Sources

  1. FDAFDA-approved label — Estrace (estradiol) via DailyMed
  2. FDAFDA-approved label — Vivelle-Dot (estradiol transdermal) via DailyMed
  3. FDAFDA-approved label — Prometrium (micronized progesterone) via DailyMed